Now, it is officially gauging interest from potential private equity and strategic bidders, according to a March 14 report from Bloomberg.
Deliberations are ongoing, and Novartis could still decide to keep its assets, including its dry eye medication Xiidra that did $487 million in sales in 2022.
In 2019, Novartis spun off its eyecare business Alcon, purchasing Xiidra in the same year.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
